secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001104659-22-002475
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond submits IND for BDTX-1535 ahead of schedule; cash runway extended to 2024
--------------------------------------------------------------------------------

- IND submitted for BDTX-1535 (CNS-penetrant EGFR inhibitor) for GBM and NSCLC; Phase 1 expected Q1 2022 subject to FDA allowance.
- Company to enroll additional patients in BDTX-189 safety expansion; Phase 2 start gated pending further data.
- Ended 2021 with ~$210M cash, sufficient to fund operations into 2024.
- Anticipates IND-enabling studies for CNS-penetrant BRAF program in 2022.
- Preclinical data shows BDTX-1535 activity in intracranial tumor models; targets ~50% of GBM patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465922002475/0001104659-22-002475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465922002475/tm222372d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-002475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer